Article
RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.
Cancer discovery - 1 Dec 2015
Cheng Haiying, Zou Yiyu, Ross Jeffrey S, Wang Kai, Liu Xuewen, Halmos Balazs, Ali Siraj M, Liu Huijie, Verma Amit, Montagna Cristina, Chachoua Abraham, Goel Sanjay, Schwartz Edward L, Zhu Changcheng, Shan Jidong, Yu Yiting, Gritsman Kira, Yelensky Roman, Lipson Doron, Otto Geoff, Hawryluk Matthew, Stephens Philip J, Miller Vincent A, Piperdi Bilal, Perez-Soler Roman
Abstract excerpt
UNLABELLED: We identified amplification of RICTOR, a key component of the mTOR complex 2 (mTORC2), as the sole actionable genomic alteration in an 18-year-old never-smoker with lung adenocarcinoma. Amplification of RICTOR occurs in 13% of lung cancers (1,016 cases) in The Cancer Genome Atlas and at a similar frequency in an independent cohort of 1,070 patients identified by genomic profiling. In the latter...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.